Neurotrope CSO to Participate in Alzheimer’s Panel at 18th Annual BIO CEO & Investor Conference

NEWARK, N.J., Feb. 04, 2016 -- Neurotrope, Inc. (NTRP) today announced that its Chief Scientific Officer, Dr. Daniel Alkon, has been invited to present on a panel focused on new directions and progress of Alzheimer’s disease research at the 18^th Annual BIO CEO & Investor Conference, being held February 8-9, 2016 at the Waldorf Astoria Hotel in New York, New York.

Dr. Alkon, who has led a 30-year career as Medical Director and Lab Chief in the U.S. National Institutes of Health (NIH) specializing in memory disorders and 14 years as founding Scientific Director of the Blanchette Rockefeller Neurosciences Institute (BRNI), will be presenting on the panel titled “Addressing Alzheimer’s Diseases: New Directions and Signs of Progress?” taking place on Monday, February 8^th 2016 at 4:00 PM EST in the Jade Room during the conference's Programs and Reception Track.

The panel aims to address how the Alzheimer’s disease field is pivoting from the failures of recent approaches to make use of new generation findings, innovative in vitro techniques, and alternative therapeutic angles.

Dr. Alkon commented, “I am honored to have the opportunity to discuss the latest research and clinical development of viable therapies for the treatment of Alzheimer’s disease, one of the most debilitating cognitive diseases we face, with a group of our peers that is unified with the common goal of developing effective treatments. After years of research and few treatment options available, we are reaching a major inflection point in identifying new approaches to attacking the disease and the panel at this year’s BIO CEO & Investor Conference exemplifies the significant interest in this field.”

Dr. Alkon continued, “Neurotrope has recently initiated a Phase 2b trial evaluating its lead drug candidate Bryostatin-1 for the treatment of moderately severe to severe Alzheimer’s disease patients, and we are excited by the prospect of demonstrating significant clinical improvement of cognition and behavior for this difficult to treat disease. Bryostatin has been shown to dynamically activate the Protein Kinase C (PKC) epsilon target, which is important because it causes a downstream effect resulting in the formation of new synapses, replacing those synapses damaged in the progression of Alzheimer’s disease.”

The BIO CEO & Investor Conference is focused on publicly traded as well as private biotech companies.  It is an investor and networking conference dedicated to providing biotechnology and life sciences companies an opportunity to present to, and meet with, institutional investors, analysts and pharmaceutical executives. The event includes plenary sessions, educational sessions, company presentations, and one-on-one meetings.

About The Blanchette Rockefeller Neurosciences Institute (BRNI)
Located in Morgantown, WV, BRNI, at West Virginia University, is a unique, independent, non-profit institute dedicated to the study of memory and finding solutions to memory disorders. BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer's patient and mother of U. S. Senator John D. Rockefeller IV. BRNI is operated in alliance with West Virginia University as well as in collaboration with other academic institutions.

About Neurotrope
Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which can result in repair of damaged synapses as well as synaptogenesis, reduction of toxic amyloid generation, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.

Neurotrope is also conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The Food and Drug Administration has granted Orphan Drug Designation to Neurotrope for bryostatin as a treatment for Fragile X Syndrome.

NTRP has exclusively licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer's disease and Fragile X Syndrome, has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease and is partnered with Stanford University to synthesize and find the next generation bryostatin – called bryologs.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing of initiation, and continued development of use of bryostatin for Alzheimer's disease and other cognitive diseases, and the Company's ability to list its common shares on a major stock exchange.  Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, the Company's inability to meet listing requirements for major stock exchanges, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition,  stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

For additional information, please contact:

The Ruth Group for Neurotrope Bioscience:

Lee Roth (Investors) / Kirsten Thomas (Media)

646-536-7012 / 508-280-6592

[email protected] / [email protected]